Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk factors for developing mineral bone disease in phenylketonuric patients.

Molecular genetics and metabolism - 1 Mar 2013

Mirás Alicia, Bóveda M Dolores, Leis María R, Mera Antonio, Aldámiz-Echevarría Luís, Fernández-Lorenzo José R, Fraga José M, Couce María L

Abstract excerpt

There is a compromised bone mass in phenylketonuria patients compared with normal population, but the mechanisms responsible are still a matter of investigation. In addition, tetrahydrobiopterin therapy is a new option for a significant proportion of these patients and the prevalence of mineral b...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopterins
Share to Bone Diseases, Metabolic
Share to Dietary Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Eicosapentaenoic Acid

Share to Minerals

Share to Osteoporosis

Share to Phenylalanine Hydroxylase

Share to Phenylketonurias

Source

Identifiers

PMID: 23352389
DOI: 10.1016/j.ymgme.2012.12.008

Genes

PAH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23352389-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk factors for developing mineral bone disease in phenylketonuric patients.PMID 23352389Read ↗

An Overview of Traditional and Novel Therapeutic Options for the Management of Phenylketonuria.Semantic proximity Read ↗

Phenylketonuria - genetic, clinical and therapeutic aspectsSemantic proximity Read ↗

Advances in the nutritional and pharmacological management of phenylketonuria.Semantic proximity Read ↗

Nutritional and Therapeutic Strategies in Paediatric Phenylketonuria: A Narrative Literature ReviewSemantic proximity Read ↗

Evaluation of Body Composition and Biochemical Parameters in Adult PKUSemantic proximity Read ↗

6R-tetrahydrobiopterin treated PKU patients below 4 years of age: Physical outcomes, nutrition and genotype.Semantic proximity Read ↗

Phenylketonuria: an update.Semantic proximity Read ↗

Co-Occurrence of Two Rare Diseases: A Child with Phenylketonuria and <italic>WNT1</italic> Osteoporosis.Semantic proximity Read ↗

What we know that could influence future treatment of phenylketonuria.Semantic proximity Read ↗

Pathogenesis of different clinical outcomes in spite of identical genotypes and comparable blood phenylalanine concentrations in phenylketonurics.Semantic proximity Read ↗

Phenylketonuria, co‐morbidity, and ageing: A reviewSemantic proximity Read ↗

Phenylalanine hydroxylase: function, structure, and regulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.